凯米生物医药(成都)有限公司2021年8月落户在成都天府国际生物城,主要从事大分子药物的开发与应用。凯米生物通过SynNeogen平台技术的开发,进行创新治疗药物的研究,用于感染性疾病和肿瘤的治疗。目前公司已完成超亿元Pre-A轮融资。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows